Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label adjunctive aticaprant in major depressive disorder
2022-000430-42Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aticaprant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoint: Adverse events including adverse events of special interest. Started Oct 2022; status: active.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2022-000430-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000430-42.